Exploring the Use of Topical Tofacitinib in Pediatric Alopecia Totalis

    Sahil Sardana
    Studysummary In this case report, a 7-year-old boy with alopecia totalis experienced significant hair regrowth after adding topical tofacitinib and mometasone to his treatment regimen, suggesting potential benefits of topical Janus kinase inhibitors for pediatric patients with this condition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Research cited in this study 5

    1. Real-World Effectiveness and Safety of Tofacitinib for Alopecia Areata: A Retrospective Cohort Study of 202 Patients Australasian Journal of Dermatology · 2024
    2. Recovery of Resistant Alopecia Areata Treated with Tofacitinib: An 8-Year-Old Child's Case Report International Journal of Trichology · 2022
    3. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    4. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
    5. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016